News

Welcome to the NNECOS Blog!

Please click on the orange RSS box below to subscribe to this blog.


  • 13 Feb 2016 10:07 AM | Lori Aubrey (Administrator)

    FDA Approves Single-Dose fosaprepitant dimeglumine

  • 13 Feb 2016 9:26 AM | Lori Aubrey (Administrator)
    2016 Medicare Updates.

    This webinar is part of The Amgen Assist®Learning Tree, which is designed to provide a variety of access and reimbursement information. Topics for this webinar will include updates to the 2016 Medicare Physician Fee Schedule and Outpatient Prospective Payment System as they relate to Amgen Oncology, as well as other Coding and Medicare developments of relevance to practice managers.

    Regional Educational Programs

  • 08 Feb 2016 3:59 PM | Lori Aubrey (Administrator)

    http://www.asco.org/advocacy/asco-joins-physician-clinical-registry-coalition-letter-regarding-senate-hit-legislation

  • 03 Feb 2016 6:56 PM | Lori Aubrey (Administrator)

    Check out this new informative video and plan to join us for the 1st annual poster session at this year's spring meeting!

    https://www.facebook.com/NNECOS/videos/786569938142354/ 


    2016 Spring Meeting

  • 28 Jan 2016 8:54 PM | Lori Aubrey (Administrator)

    http://nnecos.org/FDA

    • Approval of eribulin - liposarcoma
    • Expanded approval of nivolumab and ipilimumab
  • 13 Jan 2016 10:30 PM | Lori Aubrey (Administrator)
    https://www.une.edu/news/2015/une-dpt-students-present-project-oncology-team-central-maine-comprehensive-cancer-center


  • 13 Jan 2016 1:49 PM | Lori Aubrey (Administrator)

    We want to hear about your efforts to enhance quality, care delivery, and the patient experience. Share your innovative project, program or best practice!

    Spring Meeting Abstracts

  • 06 Jan 2016 11:53 PM | Lori Aubrey (Administrator)

    Check out our drug related resources pages!

    FDA Approvals

    Code Updates

    Packaging/Label Updates

  • 21 Dec 2015 3:59 PM | Lori Aubrey (Administrator)

    On December 18, 2015, the U. S. Food and Drug Administration (FDA) expanded the label to include the approval of pembrolizumab (Keytruda┬« Injection, Merck Sharp & Dohme Corp.) for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or metastatic melanoma with pembrolizumab. More information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software